Trial Profile

A retrospective observational cohort study Tofacitinib or TNF Inhibitors in patients with rheumatoid arthritis

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 28 Dec 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Tofacitinib (Primary) ; Adalimumab; Etanercept; Tumour necrosis factor inhibitors
Indications Rheumatoid arthritis
Focus Adverse reactions; Therapeutic Use
Acronyms RELATION

Most Recent Events

28 Dec 2022 New trial record
14 Nov 2022 Results assessing the impact of tofacitinib and TNFi on the risk of cancer outcome in patients already at-risk, particularly in the context of ORAL Surveillance which showed a higher risk for malignancies (excluding NMSC) with tofacitinib, in comparison with TNFI, in RA patients, presented at the ACR Convergence 2022.
14 Nov 2022 Results assessing major adverse cardiovascular event (MACE) occurrence in patients with rheumatoid arthritis, presented at the ACR Convergence 2022.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com